Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
RESEARCH TOOLSreports
AN2 Therapeutics, Inc. (ANTX) Stock Price & Analysis
72 Followers
ANTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.91 - $22.22
Previous Close$2.79
Volume73.66K
Average Volume (3M)141.71K
Market Cap
$83.22M
Enterprise Value-$30.99M
Total Cash (Recent Filing)$114.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 08, 2024EPS Estimate
-$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.59
Shares Outstanding29,829,040
10 Day Avg. Volume83,218
30 Day Avg. Volume141,707
Standard Deviation0.37
R-Squared0.00047
Alpha0.00599
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.43
Forecast
1Y Price Target
$4.33Price Target Upside55.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
AN2 Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Efficacy PotentialAN2 could show signs of efficacy in super refractory Mycobacterium avium complex (MAC) patients when AN2 reports their Phase 2 data.
Financial Position$118MM cash gives OpEx runway past Ph2.
Pipeline And OpportunitiesEpetraborole is a potent, rationally-designed antibiotic in Phase 2/3 for MAC NTM lung disease, and it could be the first FDA-approved oral option for the indication.
Bears Say
Clinical TrialsEnrollment in the Phase 3 portion of the trial for epetraborole is paused due to potentially low efficacy.
Drug EfficacyInitial blinded aggregate analysis from the ongoing Phase 2 study showed lower than expected culture conversion.
Regulatory ApprovalConfidence in the path forward for the indication is low, resulting in a lower rating to Market Perform.
---
Ownership Overview
43.03% Insiders
5.45% Mutual Funds
47.03% Other Institutional Investors
4.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $1.91 and its highest was $22.22 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
Currently, no data Available
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on May 14, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.06.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -$0.61.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 29,829,040 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went down -1.732%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Among the largest hedge funds holding AN2 Therapeutics, Inc.’s share is RA Capital Management. It holds AN2 Therapeutics, Inc.’s shares valued at 18M.
---
AN2 Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.33 (55.20% Upside)
$4.33 (55.20% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.77%
12-Months-Change
Fundamentals
Return on Equity
-68.38%
Trailing 12-Months
Asset Growth
33.13%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
---
ANTX Stock 12 Month Forecast
Average Price Target
$4.33
▲(55.20% Upside)
Technical Analysis
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-41.50%
upgraded a buy rating 19 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -41.50% per trade.
---